Skip to main content
. 2023 Jul 5;14:3958. doi: 10.1038/s41467-023-39761-2

Fig. 5. Lrrc4 mutation facilitates the development of rosacea in mice.

Fig. 5

a The back skins of WT and Lrrc4 L385P mutant mice intradermally injected with LL37 or control vehicle. Images were taken 48 h after the first LL37 injection. Below panels, magnified images of yellow boxed areas. b, c The severity of the rosacea-like phenotypes after first LL37 injection for 24, 36, and 48 h, was assessed with the redness area (b) and score (c) (n = 5 for each group). *P < 0.01, **P < 0.01, comparison between Lrrc4 mutant (LL37) and WT (LL37) group. b 24 h, P = 0.009; 36 h, P = 0.0197; 48 h, P = 0.0128. c 24 h, P = 0.1917; 36 h, P = 0.0109; 48 h, P = 0.0053. d Immunohistochemistry (IHC) of CD31 on skin sections from WT and Lrrc4 mutant mice treated with LL37 or control vehicle. Scale bar, 50 μm. e Quantification of relative blood vessel perimeter in the corresponding groups displayed with violin plot. n = 90–132 blood vessels from four independent mice for each group. Mutant (LL37) vs WT (LL37), P < 0.0001; WT (LL37) vs WT (Control), P < 0.0001. f HE staining of lesional skin sections from WT and mutant mice treated with LL37 or control vehicle. Scale bar, 50 μm. g Dermal infiltrating cells were quantified (n = 4 mice for each group). Mutant (LL37) vs WT (LL37), P = 0.0013; WT (LL37) vs WT (Control), P < 0.0001. All results are representative of at least three independent experiments. Data represent the mean ± SEM. *P < 0.05, **P < 0.01. Two-way ANOVA with Bonferroni’s post hoc test was used.